Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand

Earnings Call Insights: Journey Medical Corporation (DERM) Q4 2025

MANAGEMENT VIEW

* Claude Maraoui, Founder, President, CEO & Director, described 2025 as a milestone year, highlighting the successful launch of Emrosi, Journey’s internally developed oral rosacea treatment. "Emrosi was made available to pharmacies in late March of last year, and our promotional activities began in early April. I am pleased to report that during the 3 quarters of 2025 in which Emrosi was commercially available, the product achieved $14.7 million in net sales."
* Maraoui reported, "We delivered total net product revenue growth of 11%, and we improved our gross margin by nearly 3.5 percentage points compared to the 2024 period. Importantly, our business was able to make solid financial progress despite pressure on our Accutane franchise and other legacy products due to generic competition."
* The company recorded positive adjusted EBITDA as well as positive EBITDA in Q4 2025 and expects to remain adjusted EBITDA positive in 2026 and beyond. Maraoui stated, "With our solid cash position of approximately $24 million, I believe that Journey is well positioned to execute on our business plan and grow sales and profitability with the resources that we have in place."
* Prescription volume for Emrosi grew nearly 50% sequentially in Q4 versus Q3, with over 3,500 unique dermatology prescribers having written at least one script for Emrosi by year end.
* Maraoui noted, "At present, approximately 100 million commercial covered lives have access to Emrosi. This includes contracts in place with 2 of the top 3 group purchasing organizations in the United States."
* Plans to launch one or two incremental dermatology products later in 2026 were announced.
* Joseph Benesch, CFO, stated, "Total revenues for the year were $61.9 million, representing a 10% increase compared to $56.1 million for 2024. The increase reflects incremental net product revenue related to the successful U.S. commercial launch of Emrosi."

OUTLOOK

* Management expects to remain adjusted EBITDA positive in 2026 and for the foreseeable future. "As coverage expands and formulary policies mature throughout 2026, we expect to see improved reimbursement rates, reduced reliance on our co-pay bridging program and an increase in Emrosi sales and overall operating margin expansion," Maraoui explained.
* Guidance for more detailed financial metrics will be provided later in the year as visibility on downstream health plan adoption improves.

FINANCIAL RESULTS

* The company reported $61.9 million in total revenues for 2025, with gross margin at 66.2%. The year ended with $24.1 million in cash and $29.4 million in working capital.
* GAAP net loss narrowed to $11.4 million, or $0.47 per share, compared to a loss of $14.7 million, or $0.72 per share, in 2024.
* Adjusted EBITDA was a positive $2.9 million for 2025, up from $800,000 in 2024. EBITDA improved by $5.2 million year-over-year.
* SG&A expenses totaled $44.4 million, reflecting increased investment to support Emrosi’s launch and expansion.

Q&A

* Scott Henry, Alliance Global Partners: Asked about Q1 prescription trends and the impact of insurance deductible resets and weather. CEO Maraoui responded that March prescriptions have rebounded and expects Q1 prescriptions to surpass Q4 numbers, stating, "We haven't lost any steam at all, and we continue to expect substantial growth with Emrosi moving forward."
* Henry also asked about sequential momentum. Maraoui indicated, "You're going to see a nice build and momentum with this...we certainly expect to be well past that overall."
* Henry questioned revenue per script volatility. Maraoui attributed Q4’s lower figure to reimbursement mix and expects upward pressure in 2026 as reimbursement improves; new GPO contracts and the lifting of new-to-market moratoriums should benefit future revenue per script.
* Mayank Mamtani, B. Riley Securities: Asked about gross to net expectations. COO Ramsey Alloush explained, "We expect improvement throughout 2026, gradual quarter-over-quarter...as we hit certain milestones with national formularies and getting adoption for Emrosi to become a covered drug on formulary, we expect, again, incremental gain in terms of gross to net."
* Mamtani inquired about upcoming product launches and marketing spend. Maraoui indicated one or two launches likely in the second half of 2026, with expenses already included in the budget and no distraction from Emrosi as the core focus.
* Brandon Folkes, H.C. Wainwright: Asked about inventory and revenue per script trajectory. Maraoui said inventory is on track with demand and that average gross to net for 2025 was [280], within internal expectations, with upward pressure expected due to improved reimbursement.
* Thomas Flaten, Lake Street Capital: Inquired about accounts receivable and margin outlook. CFO Benesch said the increase was due to timing and expects continued gross margin improvement as high-margin products become a larger revenue share.

SENTIMENT ANALYSIS

* Analysts pressed for clarity on prescription momentum, revenue per script, and gross to net outcomes, reflecting a neutral to slightly positive tone as they acknowledged strong prescription trends but probed for sustainability and margin details.
* Management maintained a confident and forward-looking tone in both prepared remarks and Q&A, frequently referencing strong execution, market traction, and anticipated improvements: "We are planning to increase our sales force...and that should be ramped up no later than the first part of Q3," Maraoui said, signaling proactive growth efforts.
* Compared to the previous quarter, management’s tone shifted from optimistic about early traction to confident in sustaining and expanding profitability and margin improvements, while analysts maintained a pragmatic approach, seeking more granularity on financial metrics and sustainability.

QUARTER-OVER-QUARTER COMPARISON

* Emrosi’s prescription volume surged sequentially in Q4, with the unique prescriber base growing from over 2,700 in Q3 to 3,500 by year-end.
* Revenue growth slowed from 21% in Q3 to 10% for the full year, but gross margin improved by nearly 3.5 percentage points year-over-year, versus sequential improvement in prior quarters.
* Management shifted from focusing on early adoption and payer contracting in Q3 to emphasizing sustained profitability and margin expansion in Q4.
* Analysts continued to focus on revenue per script, gross to net, and payer dynamics, reflecting ongoing concern about conversion of prescription growth into sustained revenue and margin gains.
* Management outlined clear plans for new product launches and incremental sales force expansion in 2026, signaling an ongoing focus on scaling operations.

RISKS AND CONCERNS

* Management cited ongoing competitive pressure on the Accutane franchise and other legacy products due to generics.
* The conversion of prescription demand into revenue remains dependent on the pace of health plan coverage adoption and reimbursement improvements.
* Reliance on co-pay bridging programs continues until broader payer coverage is implemented, which could impact net revenue per script in the near term.
* Analysts raised concerns about gross to net improvement timing, inventory levels, and accounts receivable timing, which management addressed as being on track or due to operational timing.

FINAL TAKEAWAY

Journey Medical Corporation’s 2025 results underscore the successful commercial launch of Emrosi, with strong prescription demand, increasing prescriber adoption, and improving margins. Management expects continued EBITDA positivity, margin expansion, and sales growth in 2026 as health plan coverage matures, reimbursement improves, and the company leverages its established sales infrastructure for additional product launches. The company maintains a solid cash position and is focused on disciplined expense management while navigating ongoing challenges in legacy product lines and payer dynamics.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/derm/earnings/transcripts]

MORE ON JOURNEY MEDICAL

* Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4885940-journey-medical-corporation-derm-q4-2025-earnings-call-transcript]
* Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed [https://seekingalpha.com/article/4862086-journey-medical-emrosi-winning-stock-has-not-noticed]
* Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M [https://seekingalpha.com/news/4568908-journey-medical-non-gaap-eps-of-0_10-revenue-of-61_6m-misses-by-3_05m]
* Seeking Alpha’s Quant Rating on Journey Medical [https://seekingalpha.com/symbol/DERM/ratings/quant-ratings]
* Historical earnings data for Journey Medical [https://seekingalpha.com/symbol/DERM/earnings]